

Inventor Search
(Search history attached)

Gembah 10/539, 833


11/07/2006

=> d ibib abs ind hitstr 111 1-1

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:550873 HCAPLUS
 DOCUMENT NUMBER: 141:82339
 TITLE: Use of α -phenylthiocarboxylic and
 α -phenyloxycarboxylic acids with serum
 glucose-lowering and serum lipid-lowering activity
 INVENTOR(S): Giannessi, Fabio; Tassoni, Emanuela
 ; Tinti, Maria Ornella; Pessotto,
 Pompeo; Dell'Uomo, Natalina;
 Sciarroni, Anna Floriana; Brunetti,
 Tiziana; Milazzo, Ferdinando Maria
 PATENT ASSIGNEE(S): Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.,
 Italy
 SOURCE: PCT Int. Appl., 76 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056355	A1	20040708	WO 2003-IT820	20031216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2506627	AA	20040708	CA 2003-2506627	20031216
AU 2003288546	A1	20040714	AU 2003-288546	20031216
EP 1572180	A1	20050914	EP 2003-780669	20031216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017359	A	20051108	BR 2003-17359	20031216
CN 1728992	A	20060201	CN 2003-80106699	20031216
JP 2006512362	T2	20060413	JP 2004-561981	20031216
PRIORITY APPLN. INFO.:			IT 2002-RM629	A 20021219
			WO 2003-IT820	W 20031216

OTHER SOURCE(S): MARPAT 141:82339
 GI



AB The invention describes the use of derivs. of α -phenylthiocarboxylic and α -phenyloxycarboxylic acids I [R = H, (un)substituted]

(hetero)aryl; n = 0-3; p = 0, 1; X = OH, O-(C1-4 alkyl); R1, R2 = H, C1-5 alkyl, COX; Q = NH, O, S, NHC(O)O, etc.; Y = O, S] for the preparation of a medicament for the prophylaxis and treatment of diabetes, particularly type 2 diabetes, its complications, the various forms of insulin resistance, and hyperlipidemias. Compound preparation is also described.

- IC ICM A61K031-19
ICS C07C053-134; C07C327-16; A61P003-06; A61P003-08; A61P003-10
CC 1-10 (Pharmacology)
Section cross-reference(s): 25
ST phenylthiocarboxylate phenyloxycarboxylate deriv prepn hypoglycemic
hypolipidemic; insulin resistance hyperlipidemia treatment
phenylthiocarboxylate phenyloxycarboxylate deriv; antidiabetic NIDDM
phenylthiocarboxylate phenyloxycarboxylate deriv
IT Antiarteriosclerotics
(antiatherosclerotics; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Drug delivery systems
(capsules; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Drug delivery systems
(controlled-release; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Artery, disease
(coronary; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Drug delivery systems
(depot; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Blood vessel, disease
(diabetic macroangiopathy; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Blood vessel, disease
(diabetic microangiopathy; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Kidney, disease
(diabetic nephropathy; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Nerve, disease
(diabetic neuropathy; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Eye, disease
(diabetic retinopathy; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Drug delivery systems
(emulsions; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Liver, disease
(fatty; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Drug delivery systems
(implants; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
IT Heart, disease
(infarction; phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)

- IT Drug delivery systems
 - (injections, s.c.; phenylthiocarboxylic and phenoxyacarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
- IT Drug delivery systems
 - (injections; phenylthiocarboxylic and phenoxyacarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
- IT Drug delivery systems
 - (liposomes; phenylthiocarboxylic and phenoxyacarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
- IT Drug delivery systems
 - (liqs.; phenylthiocarboxylic and phenoxyacarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
- IT Metabolic disorders
 - (metabolic syndrome X; phenylthiocarboxylic and phenoxyacarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
- IT Liver, disease
 - (non-alc. fatty liver disease; phenylthiocarboxylic and phenoxyacarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
- IT Diabetes mellitus
 - (non-insulin-dependent; phenylthiocarboxylic and phenoxyacarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
- IT Hepatitis
 - (nonalc. steatohepatitis; phenylthiocarboxylic and phenoxyacarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
- IT Drug delivery systems
 - (oral; phenylthiocarboxylic and phenoxyacarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
- IT Drug delivery systems
 - (parenterals; phenylthiocarboxylic and phenoxyacarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
- IT Blood vessel, disease
 - (peripheral; phenylthiocarboxylic and phenoxyacarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
- IT Anticholesteremic agents
 - Antidiabetic agents
 - Antihypertensives
 - Antibesity agents
 - Atherosclerosis
 - Cardiovascular agents
 - Diabetes mellitus
 - Hypercholesterolemia
 - Hyperglycemia
 - Hypertension
 - Hypolipemic agents
 - Nervous system agents
 - Obesity
 - (phenylthiocarboxylic and phenoxyacarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
- IT Glycerides, biological studies
 - High-density lipoproteins
 - Hyperlipidemia
 - RL: BSU (Biological study, unclassified); BIOL (Biological study)
 - (phenylthiocarboxylic and phenoxyacarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)
- IT Ovary, disease
 - (polycystic; phenylthiocarboxylic and phenoxyacarboxylic acid derivs.)

with serum glucose-lowering and serum lipid-lowering activity)

IT Drug delivery systems
 (powders; phenylthiocarboxylic and phenoxyacrylic acid derivs.
 with serum glucose-lowering and serum lipid-lowering activity)

IT Drug delivery systems
 (solids; phenylthiocarboxylic and phenoxyacrylic acid derivs. with
 serum glucose-lowering and serum lipid-lowering activity)

IT Drug delivery systems
 (solns.; phenylthiocarboxylic and phenoxyacrylic acid derivs. with
 serum glucose-lowering and serum lipid-lowering activity)

IT Brain, disease
 (stroke; phenylthiocarboxylic and phenoxyacrylic acid derivs. with
 serum glucose-lowering and serum lipid-lowering activity)

IT Drug delivery systems
 (suspensions; phenylthiocarboxylic and phenoxyacrylic acid derivs.
 with serum glucose-lowering and serum lipid-lowering activity)

IT Drug delivery systems
 (syrups; phenylthiocarboxylic and phenoxyacrylic acid derivs. with
 serum glucose-lowering and serum lipid-lowering activity)

IT Drug delivery systems
 (tablets, coated; phenylthiocarboxylic and phenoxyacrylic acid
 derivs. with serum glucose-lowering and serum lipid-lowering activity)

IT Drug delivery systems
 (tablets; phenylthiocarboxylic and phenoxyacrylic acid derivs.
 with serum glucose-lowering and serum lipid-lowering activity)

IT Peroxisome proliferator-activated receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (α ; phenylthiocarboxylic and phenoxyacrylic acid derivs.
 with serum glucose-lowering and serum lipid-lowering activity)

IT Peroxisome proliferator-activated receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (γ ; phenylthiocarboxylic and phenoxyacrylic acid derivs.
 with serum glucose-lowering and serum lipid-lowering activity)

IT 50-99-7, D-Glucose, biological studies 4429-04-3,
 Fructosamine
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (phenylthiocarboxylic and phenoxyacrylic acid derivs. with serum
 glucose-lowering and serum lipid-lowering activity)

IT 566189-21-7P 566189-22-8P 566189-23-9P
 566189-32-0P 566189-35-3P 566189-36-4P
 566189-42-2P 566189-43-3P 566189-44-4P
 714912-30-8P 714912-31-9P 714912-32-0P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (phenylthiocarboxylic and phenoxyacrylic acid derivs. with serum
 glucose-lowering and serum lipid-lowering activity)

IT 566189-24-0P 566189-39-7P 566189-41-1P
 566189-45-5P 714912-24-0P 714912-25-1P
 714912-26-2P 714912-27-3P 714912-28-4P
 714912-29-5P 714912-33-1P 714912-34-2P
 714912-35-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (phenylthiocarboxylic and phenoxyacrylic acid derivs. with serum
 glucose-lowering and serum lipid-lowering activity)

IT 120-72-9, Indole, reactions 540-51-2, 2-Bromoethanol
 637-89-8, 4-Mercaptophenol 1484-14-6,
 9H-Carbazole-9-ethanol 1485-07-0, 2-(2-Naphthyl)ethanol

1875-88-3, 4-Chlorophenethyl alcohol 2493-04-1,
 5-Nitrofurfuryl alcohol 23426-63-3, Methyl 2-bromoisobutyrate
 40248-84-8, 3-Mercaptophenol 81156-68-5,
 2,4-Dichlorophenethyl alcohol 374818-89-0 714912-36-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum
 glucose-lowering and serum lipid-lowering activity)

IT 121459-15-2P, 1-(2-Hydroxyethyl)indole 566189-18-2P
 566189-20-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum
 glucose-lowering and serum lipid-lowering activity)


IT 12619-70-4D, Cyclodextrin, complexes
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum
 glucose-lowering and serum lipid-lowering activity)

IT 9004-10-8, Insulin, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (resistance; phenylthiocarboxylic and phenyloxycarboxylic acid derivs.
 with serum glucose-lowering and serum lipid-lowering activity)

IT 50-99-7, D-Glucose, biological studies 4429-04-3,
 Fructosamine
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum
 glucose-lowering and serum lipid-lowering activity)


RN 50-99-7 HCPLUS
 CN D-Glucose (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 4429-04-3 HCPLUS
 CN D-Fructose, 1-amino-1-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 566189-21-7P 566189-22-8P 566189-23-9P
 566189-32-0P 566189-35-3P 566189-36-4P
 566189-42-2P 566189-43-3P 566189-44-4P
 714912-30-8P 714912-31-9P 714912-32-0P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum


glucose-lowering and serum lipid-lowering activity)
 RN 566189-21-7 HCPLUS
 CN Propanoic acid, 2-[[4-[2-(4-chlorophenyl)ethoxy]phenyl]thio]-2-methyl-,
 methyl ester (9CI) (CA INDEX NAME)




RN 566189-22-8 HCPLUS
 CN Propanoic acid, 2-[[4-[2-(1H-indol-1-yl)ethoxy]phenyl]thio]-2-methyl-,
 methyl ester (9CI) (CA INDEX NAME)




RN 566189-23-9 HCPLUS
 CN Propanoic acid, 2-methyl-2-[[4-[2-(2-naphthalenyl)ethoxy]phenyl]thio]-,
 methyl ester (9CI) (CA INDEX NAME)



RN 566189-32-0 HCPLUS
 CN Propanoic acid, 2-methyl-2-[[3-[2-(2-naphthalenyl)ethoxy]phenyl]thio]-,
 methyl ester (9CI) (CA INDEX NAME)




RN 566189-35-3 HCPLUS
 CN Propanoic acid, 2-[[3-[2-(4-chlorophenyl)ethoxy]phenyl]thio]-2-methyl-,
 methyl ester (9CI) (CA INDEX NAME)




RN 566189-36-4 HCAPLUS

CN Propanoic acid, 2-[(3-[2-(1H-indol-1-yl)ethoxy]phenyl]thio]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 566189-42-2 HCAPLUS

CN Propanoic acid, 2-[(4-[2-(2,4-dichlorophenoxy)ethoxy]phenyl]thio]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 566189-43-3 HCAPLUS

CN Propanoic acid, 2-[(3-[2-(2,4-dichlorophenoxy)ethoxy]phenyl]thio]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 566189-44-4 HCAPLUS


CN Propanoic acid, 2-[(3-[2-(9H-carbazol-9-yl)ethoxy]phenyl]thio]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 714912-30-8 HCAPLUS
 CN Propanoic acid, 2-[(4-[2-(5-methoxy-1H-indol-1-yl)ethoxy]phenyl)thio]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 714912-31-9 HCAPLUS
 CN Propanoic acid, 2-methyl-2-[(4-[2-[5-(phenylmethoxy)-1H-indol-1-yl]ethoxy]phenyl)thio]-, methyl ester (9CI) (CA INDEX NAME)



RN 714912-32-0 HCAPLUS
 CN Propanoic acid, 2-methyl-2-[(3-[[5-(4-nitrophenyl)-2-furanyl]oxy]phenyl)thio]-, methyl ester (9CI) (CA INDEX NAME)



IT 566189-24-0P 566189-39-7P 566189-41-1P


566189-45-5P 714912-24-0P 714912-25-1P
 714912-26-2P 714912-27-3P 714912-28-4P
 714912-29-5P 714912-33-1P 714912-34-2P
 714912-35-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)


RN 566189-24-0 HCAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[2-(2-naphthalenyl)ethoxy]phenyl]thio]-
 (9CI) (CA INDEX NAME)




RN 566189-39-7 HCAPLUS

CN Propanoic acid, 2-[[4-[2-(4-chlorophenyl)ethoxy]phenyl]thio]-2-methyl-
 (9CI) (CA INDEX NAME)




RN 566189-41-1 HCAPLUS

CN Propanoic acid, 2-[[3-[2-(4-chlorophenyl)ethoxy]phenyl]thio]-2-methyl-
 (9CI) (CA INDEX NAME)




RN 566189-45-5 HCAPLUS


CN Propanoic acid, 2-[[4-[2-(9H-carbazol-9-yl)ethoxy]phenyl]thio]-2-methyl-,
 methyl ester (9CI) (CA INDEX NAME)




RN 714912-24-0 HCAPLUS
 CN Propanoic acid, 2-[(3-[2-(2,4-dichlorophenyl)ethoxy]phenyl]thio]-2-methyl-
 (9CI) (CA INDEX NAME)



RN 714912-25-1 HCAPLUS
 CN Propanoic acid, 2-[(4-[2-(2,4-dichlorophenyl)ethoxy]phenyl]thio)-2-methyl-
 (9CI) (CA INDEX NAME)




RN 714912-26-2 HCAPLUS
 CN Propanoic acid, 2-[(3-[2-(9H-carbazol-9-yl)ethoxy]phenyl]thio)-2-methyl-
 (9CI) (CA INDEX NAME)




RN 714912-27-3 HCAPLUS

CN Propanoic acid, 2-[(4-[2-(1H-indol-1-yl)ethoxy]phenyl)thio]-2-methyl- (9CI) (CA INDEX NAME)




RN 714912-28-4 HCAPLUS

CN Propanoic acid, 2-[(3-[2-(1H-indol-1-yl)ethoxy]phenyl)thio]-2-methyl- (9CI) (CA INDEX NAME)




RN 714912-29-5 HCAPLUS

CN Propanoic acid, 2-methyl-2-[(3-[2-(2-naphthalenyl)ethoxy]phenyl)thio]- (9CI) (CA INDEX NAME)




RN 714912-33-1 HCAPLUS

CN Propanoic acid, 2-[(4-[2-(5-methoxy-1H-indol-1-yl)ethoxy]phenyl)thio]-2-methyl- (9CI) (CA INDEX NAME)




RN 714912-34-2 HCAPLUS

CN Propanoic acid, 2-methyl-2-[(4-[2-[5-(phenylmethoxy)-1H-indol-1-yl]ethoxy]phenyl)thio]- (9CI) (CA INDEX NAME)



RN 714912-35-3 HCAPLUS

CN Propanoic acid, 2-methyl-2-[[3-[[5-(4-nitrophenyl)-2-furanyl]oxy]phenyl]thio]- (9CI) (CA INDEX NAME)



IT 120-72-9, Indole, reactions 540-51-2, 2-Bromoethanol

637-89-8, 4-Mercaptophenol 1484-14-6,

9H-Carbazole-9-ethanol 1485-07-0, 2-(2-Naphthyl)ethanol

1875-88-3, 4-Chlorophenethyl alcohol 2493-04-1,

5-Nitrofurfuryl alcohol 23426-63-3, Methyl 2-bromoisobutyrate

40248-84-8, 3-Mercaptophenol 81156-68-5,


2,4-Dichlorophenethyl alcohol 374818-89-0 714912-36-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)


RN 120-72-9 HCAPIUS

CN 1H-Indole (9CI) (CA INDEX NAME)




RN 540-51-2 HCAPIUS


CN Ethanol, 2-bromo- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




RN 637-89-8 HCAPLUS
 CN Phenol, 4-mercaptop- (9CI) (CA INDEX NAME)




RN 1484-14-6 HCAPLUS
 CN 9H-Carbazole-9-ethanol (9CI) (CA INDEX NAME)




RN 1485-07-0 HCAPLUS
 CN 2-Naphthaleneethanol (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




RN 1875-88-3 HCAPLUS
 CN Benzeneethanol, 4-chloro- (9CI) (CA INDEX NAME)




RN 2493-04-1 HCAPLUS
 CN 2-Furanmethanol, 5-nitro- (9CI) (CA INDEX NAME)




RN 23426-63-3 HCAPLUS
 CN Propanoic acid, 2-bromo-2-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 40248-84-8 HCAPLUS
CN Phenol, 3-mercaptop- (9CI) (CA INDEX NAME)




RN 81156-68-5 HCAPLUS
CN Benzeneethanol, 2,4-dichloro- (9CI) (CA INDEX NAME)



RN 374818-89-0 HCAPLUS
CN 1H-Indole-1-ethanol, 5-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 714912-36-4 HCAPLUS
CN 1H-Indole-1-ethanol, 5-methoxy- (9CI) (CA INDEX NAME)




IT 121459-15-2P, 1-(2-Hydroxyethyl)indole 566189-18-2P
566189-20-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum
glucose-lowering and serum lipid-lowering activity)
RN 121459-15-2 HCAPLUS

CN 1H-Indole-1-ethanol (9CI) (CA INDEX NAME)




RN 566189-18-2 HCPLUS

CN Propanoic acid, 2-[(4-hydroxyphenyl)thio]-2-methyl-, methyl ester (9CI)
(CA INDEX NAME)



RN 566189-20-6 HCPLUS

CN Propanoic acid, 2-[(3-hydroxyphenyl)thio]-2-methyl-, methyl ester (9CI)
(CA INDEX NAME)



IT 12619-70-4D, Cyclodextrin, complexes

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phenylthiocarboxylic and phenoxythiocarboxylic acid derivs. with serum
glucose-lowering and serum lipid-lowering activity)

RN 12619-70-4 HCPLUS

CN Cyclodextrin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 9004-10-8, Insulin, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(resistance; phenylthiocarboxylic and phenoxythiocarboxylic acid derivs.
with serum glucose-lowering and serum lipid-lowering activity)

RN 9004-10-8 HCPLUS

CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:33:15 ON 11 JUL 2006)

FILE 'HCAPLUS' ENTERED AT 15:33:32 ON 11 JUL 2006

E GIANNESI FABIO/AU

L1 54 S E2-3

E TASSONI EMANUELA/AU

L2 24 S E2-3

E TINTI MARIA ORNELLA/AU

L3 94 S E2-4

E PESSOTTO POMPEO/AU

L4 16 S E2-3

E DELLUOMO NATALINA/AU

E DELL UOMO NATALINA/AU

L5 14 S E3

E SCIARRONI ANNA FLORIANA/AU

L6 9 S E2-4

E BRUNETTI TIZIANA/AU

L7 6 S E2-3

E MILAZZO FERDINANDO MARIA/AU

L8 5 S E1-3

L9 2 S L1 AND L2 AND L3 AND L4 AND L5 AND L6 AND L7 AND L8

SELECT RN L9 2

FILE 'REGISTRY' ENTERED AT 15:36:01 ON 11 JUL 2006

L10 44 S E1-44

FILE 'HCAPLUS' ENTERED AT 15:36:16 ON 11 JUL 2006

L11 1 S L9 AND L10

L12 ANALYZE L11 1-1 CT : 30 TERMS


539,833

Gitomer 10/343,555

17/07/2006

=> d

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 566189-21-7 REGISTRY
ED Entered STN: 14 Aug 2003
CN Propanoic acid, 2-[[4-[2-(4-chlorophenyl)ethoxy]phenyl]thio]-2-methyl-,
methyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H21 Cl O3 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)


ED Entered STN: 14 Aug 2003

=> d ibib abs hitstr 18 1-2

L8 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:550873 HCAPLUS
 DOCUMENT NUMBER: 141:82339
 TITLE: Use of α -phenylthiocarboxylic and
 α -phenyloxycarboxylic acids with serum
 glucose-lowering and serum lipid-lowering activity
 INVENTOR(S): Giannessi, Fabio; Tassoni, Emanuela; Tinti, Maria
 Ornella; Pessotto, Pompeo; Dell'Uomo, Natalina;
 Sciarroni, Anna Floriana; Brunetti, Tiziana; Milazzo,
 Ferdinando Maria
 PATENT ASSIGNEE(S): Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.,
 Italy
 SOURCE: PCT Int. Appl., 76 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056355	A1	20040708	WO 2003-IT820	20031216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2506627	AA	20040708	CA 2003-2506627	20031216
AU 2003288546	A1	20040714	AU 2003-288546	20031216
EP 1572180	A1	20050914	EP 2003-780669	20031216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017359	A	20051108	BR 2003-17359	20031216
CN 1728992	A	20060201	CN 2003-80106699	20031216
JP 2006512362	T2	20060413	JP 2004-561981	20031216
US 2006154979	A1	20060713	US 2005-539833	20050719
PRIORITY APPLN. INFO.:			IT 2002-RM629	A 20021219
			WO 2003-IT820	W 20031216

OTHER SOURCE(S): MARPAT 141:82339
 GI



AB The invention describes the use of derivs. of α -phenylthiocarboxylic and α -phenyloxycarboxylic acids I [R = H, (un)substituted


(hetero)aryl; n = 0-3; p = 0, 1; X = OH, O-(C1-4 alkyl); R1, R2 = H, C1-5 alkyl, COX; Q = NH, O, S, NHC(O)O, etc.; Y = O, S] for the preparation of a medicament for the prophylaxis and treatment of diabetes, particularly type 2 diabetes, its complications, the various forms of insulin resistance, and hyperlipidemias. Compound preparation is also described.

IT 566189-21-7P 566189-42-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)


RN 566189-21-7 HCPLUS

CN Propanoic acid, 2-[(4-[2-(4-chlorophenyl)ethoxy]phenyl]thio]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 566189-42-2 HCPLUS

CN Propanoic acid, 2-[(4-[2-(2,4-dichlorophenyl)ethoxy]phenyl]thio]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)




IT 566189-39-7P 714912-25-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phenylthiocarboxylic and phenyloxycarboxylic acid derivs. with serum glucose-lowering and serum lipid-lowering activity)

RN 566189-39-7 HCPLUS


CN Propanoic acid, 2-[(4-[2-(4-chlorophenyl)ethoxy]phenyl]thio]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 714912-25-1 HCPLUS

CN Propanoic acid, 2-[(4-[2-(2,4-dichlorophenyl)ethoxy]phenyl]thio)-2-methyl-, methyl ester (9CI) (CA INDEX NAME)

(9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 2 HCPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:570951 HCPLUS
 DOCUMENT NUMBER: 139:133346
 TITLE: Preparation of derivatives of α -phenylthiocarboxylic and α -phenyloxycarboxylic acids useful for the treatment of diseases responding to PPAR α activation
 INVENTOR(S): Giannessi, Fabio; Dell'Uomo, Natalina; Tassoni, Emanuela; Tinti, Maria Ornella; Sciarroni, Anna Floriana; Bandera, Monica; Pessotto, Pompeo; Arduini, Arduino
 PATENT ASSIGNEE(S): Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Italy
 SOURCE: PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003059875	A2	20030724	WO 2003-IT11	20030115
WO 2003059875	A3	20031204		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2472223	AA	20030724	CA 2003-2472223	20030115
AU 2003209679	A1	20030730	AU 2003-209679	20030115
EP 1474387	A2	20041110	EP 2003-729547	20030115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003006824	A	20041221	BR 2003-6824	20030115
JP 2005514456	T2	20050519	JP 2003-559979	20030115
CN 1620429	A	20050525	CN 2003-802289	20030115
US 2005054671	A1	20050310	US 2004-501472	20041110
PRIORITY APPLN. INFO.:			IT 2002-RM14	A 20020115

OTHER SOURCE(S):
GI

MARPAT 139:133346

WO 2003-IT11

W 20030115




AB Title compds. I [R = H, YCR5R6COX, mono- bi- tricyclic (hetero)aryl; m = 0-1; n = 0-3; when n = 1, R3-4 = H, alkyl, when n = 2-3, R3 = R4 = H; p = 0-1; X = OH, alkoxy; R1-2, R5-6 = H, alkyl, alkoxy, acyl, etc.; Q, Z = NH, O, S, amido, etc.; Y = O, S] are prepared For instance, 4-mercaptophenol is reacted with Me α -bromoisobutyrate (CH3CN, NaH) to give Me 2-(4-hydroxyphenylthio)isobutyrate. Selected compds. exhibit PPAR α agonist activity at 2 μ M. I are useful for the treatment of heart failure, the hyperlipemias and atherosclerosis.

IT 566189-21-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of derivs. of α -phenylthiocarboxylic and α -phenyloxycarboxylic acids as PPAR α agonists)

RN 566189-21-7 HCPLUS

CN Propanoic acid, 2-[(4-[2-(4-chlorophenyl)ethoxy]phenyl]thio]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)




IT 566189-39-7P, 2-[(4-[2-(4-Chlorophenyl)ethoxy]phenyl]thio]-2-methylpropanoic acid 566189-42-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of derivs. of α -phenylthiocarboxylic and α -phenyloxycarboxylic acids as PPAR α agonists)


RN 566189-39-7 HCPLUS

CN Propanoic acid, 2-[(4-[2-(4-chlorophenyl)ethoxy]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)




RN 566189-42-2 HCPLUS

CN Propanoic acid, 2-[[4-[2-(2,4-dichlorophenyl)ethoxy]phenyl]thio]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)



=> d que stat 18
 L5 STR



NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE
 L7 4 SEA FILE=REGISTRY SSS FUL L5
 L8 2 SEA FILE=HCAPLUS ABB=ON L7

=> d his ful

(FILE 'HOME' ENTERED AT 14:24:55 ON 17 JUL 2006)

FILE 'REGISTRY' ENTERED AT 14:25:11 ON 17 JUL 2006

L1 STRUCTURE 566189-21-7
L2 0 SEA SSS SAM L1
L3 0 SEA SSS SAM L1
L4 1 SEA ABB=ON 566189-21-7/RN
 D
L5 STRUCTURE 566189-21-7
L6 0 SEA SSS SAM L5
L7 4 SEA SSS FUL L5
 D SCAN

FILE 'HCAPLUS' ENTERED AT 14:33:00 ON 17 JUL 2006

L8 2 SEA ABB=ON L7
 D AU 1-2
 D IBIB ABS HITSTR L8 1-2
 D QUE STAT L8

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JUL 2006 HIGHEST RN 892755-86-1

DICTIONARY FILE UPDATES: 14 JUL 2006 HIGHEST RN 892755-86-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Jul 2006 VOL 145 ISS 4

FILE LAST UPDATED: 16 Jul 2006 (20060716/ED)

Gembeh 10/539,833

17/07/2006

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.